The Impact of a Nationwide Blood Culture Bottle Shortage in 2024 on Healthcare Facilities in the United States
- PMID: 40929077
- PMCID: PMC12478280
- DOI: 10.1093/cid/ciaf498
The Impact of a Nationwide Blood Culture Bottle Shortage in 2024 on Healthcare Facilities in the United States
Abstract
Background: A shortage of BD BACTECTM blood culture bottles occurred in 2024. We describe the clinical impact of that shortage.
Methods: We conducted a National Healthcare Safety Network (NHSN) questionnaire and retrospective cohort study using inpatient hospitalization data from the Premier Healthcare Database. In the retrospective cohort, facilities were categorized into BD BACTEC™ (n = 11) and non-BD BACTEC™ (n = 28) hospitals; non-shortage and shortage periods were considered from May 2023 to June 2024 and July to November 2024. We used a generalized linear model for the rate of blood cultures with an offset for patient days and adjusted for facility characteristics and other factors. Similarly, we modeled the rate of unique adult hospitalizations with a pathogen-positive blood culture per hospitalization.
Results: Of 3196 facilities responding, 1453 (45.6%) indicated a use of BD BACTECTM to the NHSN questionnaire; of those, 1103 (75.8%) reported a shortage impact. In the retrospective cohort study, there was a 27.4% decrease in cultures at BD BACTEC™ hospitals during the shortage period (95% CI: -31.2% to -23.4%). BD BACTEC™ facilities had a median change in culturing rate of -33.3% (IQR: -47.0% to 2.0%) between the non-shortage and shortage periods. There was a 15.3% decrease in the rate of patients positive for a pathogen at affected facilities during the shortage (95% CI: -22.4% to -7.5%).
Conclusions: BD BACTEC™ facilities experienced substantial and non-uniform decreases in blood culture rates. Impacted facilities had a decrease in the rate of observed bloodstream infections, which has implications for patient safety and surveillance.
Keywords: blood culture bottles; blood cultures; diagnostic stewardship; questionnaire; supply shortage.
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2025.
Conflict of interest statement
J.D.L. reports institutional support for travel to the Society for Healthcare Epidemiology of America Spring meeting and Clinical and Laboratory Standards Institute antimicrobial susceptibility testing subcommittee meetings. All other authors report no conflicts of interest.
Figures
References
-
- Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015; 132:1435–1486. - PubMed
-
- Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021; 49:e1063–e1143. - PubMed
-
- Fabre V, Sharara SL, Salinas AB, et al. Does This Patient Need Blood Cultures? A Scoping Review of Indications for Blood Cultures in Adult Nonneutropenic Inpatients. Clin Infect Dis 2020; 71:1339–1347. - PubMed
-
- Miller JM, Binnicker MJ, Campbell S, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis 2024; ciae104 (Online ahead of print). - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
